Case of paradoxical adverse response to mepolizumab with mepolizumab-induced alopecia in severe eosinophilic asthma

BMJ Case Rep. 2020 Feb 20;13(2):e233161. doi: 10.1136/bcr-2019-233161.

Abstract

Recent years have seen an increase in use of mepolizumab and other biological therapies for the treatment of severe eosinophilic asthma. A few cases of paradoxical responses to mepolizumab therapy have now been reported and are hypothesised as being a response to immune complex formation. We present a case of mepolizumab-induced alopecia in a patient with paradoxical adverse response to mepolizumab given for severe eosinophilic asthma. We postulate this could be secondary to autoimmune mechanisms and that it could help herald poor response to treatment, thereby facilitating early identification of patients having paradoxical responses.

Keywords: asthma; drugs: respiratory system; unwanted effects/adverse reactions.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Africa, Northern / ethnology
  • Alopecia / chemically induced*
  • Anti-Asthmatic Agents / adverse effects*
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Asthma / drug therapy*
  • Female
  • Humans
  • Myalgia / chemically induced
  • Pulmonary Eosinophilia / drug therapy*
  • United Kingdom / epidemiology

Substances

  • Anti-Asthmatic Agents
  • Antibodies, Monoclonal, Humanized
  • benralizumab
  • mepolizumab